Gil Roth07.19.07
2007 Top 20 Pharmaceutical Companies Report
Pfizer's at the top of the roost, but one hare-brained mega-acquisition by GlaxoSmithKline or Sanofi could topple them. Companies #2-5 are all foreign, but seven of the next eight are based in the U.S.; I have no idea what that's supposed to signify. Demonstrating how tough it is to stay at the top, only four companies in the top 10 reached double-digit sales growth.
|
|
The largest increase in revenues was Novartis' $3.3 billion, but almost 30% of that came from its purchase of Chiron. GSK had the greatest "organic" growth, adding $3.0 billion in revenues. Bristol-Myers Squibb and Abbott Laboratories suffered the most last year, shedding $1.4 billion and $1.3 billion in revenues, respectively.
Several companies near the bottom of our list moved up thanks to strategic acquisitions; Bayer's purchase of Schering AG led to the biggest jump by any company on the list, from #20 to #16. Let's hope no one else gets any bright ideas . . .
—Gil Y. Roth, Editor
| Top 20 Pharmaceutical Companies | ||
| 01 | Pfizer | $45,083 |
| 02 | GlaxoSmithKline | $37,003 |
| 03 | Sanofi-Aventis | $35,643 |
| 04 | AstraZeneca | $25,741 |
| 05 | Novartis | $23,532 |
| 06 | Merck | $23,425 |
| 07 | Johnson & Johnson | $23,267 |
| 08 | Roche | $19,300 |
| 09 | Wyeth | $15,683 |
| 10 | Eli Lilly & Co. | $14,816 |
| 11 | Bristol-Myers Squibb | $13,861 |
| 12 | Abbott Laboratories | $12,395 |
| 13 | Schering-Plough | $10,461 |
| 14 | Boehringer-Ingelheim | $10,440 |
| 15 | Takeda | $9,793 |
| 16 | Bayer AG | $8,518 |
| 17 | Astellas | $7,862 |
| 18 | Daiichi-Sankyo | $7,166 |
| 19 | Eisai | $5,589 |
| 20 | Merck KgA | $4,674 |
Based on 2006 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the online edition, pipeline and patent expiry info is only available for companies #1-5.
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Abbott Laboratories and Boehringer-Ingelheim, by Kristin Brooks.
All pipeline information compiled by Kristin Brooks
Photo courtesy of Bristol-Myers Squibb
